Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm

This article was originally published in The Pink Sheet Daily

Executive Summary

Sale is the second of three units Genzyme said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers.

You may also be interested in...

Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit

Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.

Sekisui Chemical To Acquire U.S. CRO XenoTech

TOKYO - In an effort to expand its U.S. presence in preclinical services, Sekisui Chemical Co. says it plans to acquire Kansas-based contract research organization XenoTech in an undisclosed, all-cash transaction by the end of July

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts